Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 May 2019
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Salix Pharmaceuticals
- 07 Feb 2011 New trial record